Lannett Company, Inc. (NYSE: LCI) today announced that it expects to commence marketing in the coming months a generic version of Adderall XR®, an extended-release mixed salt of a single entity Amphetamine tablet product (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate), with strengths of 5 mg, 10 mg, 15 mg, 20 mg, 25 mg and 30 mg tablets. Adderall XR® including generic versions have an estimated IQVIA market value of approximately $1.3 billion for the 12 months ending October 2019, although actual generic market values are expected to be lower.
“Our strategic alliance partners already have received FDA approval for generic Adderall XR®, paving the way for a near-term launch,” said Tim Crew, chief executive officer of Lannett. “Generic Adderall XR® complements our previously launched generic Adderall® immediate release (IR) and is included in the dozen or so products we expect to launch by the end of our current fiscal year. While the Adderall XR market is sizable, there currently are several generic suppliers for this product.”
In March 2019, Lannett entered into an agreement with Elite Pharmaceuticals and SunGen Pharma to be the exclusive U.S. distributor of certain drug products, including generic Adderall® IR and generic Adderall XR®. Under the agreement, Lannett primarily provides sales, marketing and distribution support for the products, for which it receives a share of the profits.
Adderall XR®, a registered trademark of Shire Plc, is a central nervous system (CNS) stimulant, indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.